Grünenthal opens Innovation Hub in Boston

Grünenthal, the German family-owned leader in pain, says that it has opened a new Innovation Hub in the Greater Boston area, USA.

Through this Innovation Hub, Grünenthal aims to identify promising projects in pain, inflammation, orphan diseases, and devices and technologies from the large number of projects in late discovery and early development in the region. By building collaborative networks, in close partnership with institutions in the Boston area – from entrepreneurial scientists to successful spin-outs and start-ups – Grünenthal will drive these projects through R&D in order to address the need for innovation.

The opening of the Greater Boston Innovation Hub is part of Grünenthal’s strategy to build relationships in geographic areas with a high number of potential research, development and licensing partners. This Innovation Hub will be driven by the company’s Innovative Medicines Unit (IMU), a group tasked with building Grünenthal’s late discovery and early development pipeline through strategic collaborations with external partners. The Hub concept is a crucial part of Grünenthal’s ambition to deliver four to five new products to patients, and become a 2 billion ($2.18 billion) company by 2022.